C-Reactive Protein Serum Level is a Valuable and Simple Prognostic Marker in Non Hodgkin's Lymphoma
- 1 January 1998
- journal article
- clinical trial
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 31 (3-4), 351-357
- https://doi.org/10.3109/10428199809059228
Abstract
Interleukin-6 plays a central role in normal B-cell maturation and in proliferation of some B-cell malignancies including multiple myeloma and some non Hodgkin's lymphomas (NHL). Furthermore, this cytokine also plays a major role in acute phase response by mediating synthesis of acute phase proteins such as C-reactive protein (CRP). In order to evaluate the exact role of CRP serum level as a simple prognostic factor, we analyzed CRP and IL-6 serum levels in 39 patients with NHL. Eleven patients had low grade NHL, 15 intermediate grade NHL, and 13 high grade NHL. Thirty percent of the patients presented detectable IL-6 serum levels (mean ± SD: 33.6 ± 95.2 U/ml, range: 0 to 500). Increased serum CRP levels were found in 42% of the patients with a mean of 29.2 ± 41.97 mg/1 (range: 0 to 129). Thirty seven patients were studied for both markers. Three groups of patients were determined. One with low IL-6 and CRP serum levels (N=21), a second with high level of both markers (N=10), and the third with high serum CRP levels alone (N = 5). Only one patient had high level of serum IL-6 with no detectable CRP. The correlation of serum IL-6 and CRP levels with patient survival was investigated. Median survival in the group with low IL-6 level was not reached. 67% of patients of this group were still alive at 32 months from diagnosis. The group of patients with detectable IL-6 had a median of survival of 12 months (p<0.025). The survival of patients with a CRP<10 mg/1 was not reached. 75% of patients survive at 32 months from diagnosis, whereas the group with higher CRP level reached a median survival at 8.5 months (p<0.009). As expected, on univariate analysis, there is a significant relationship between CRP and IL-6 levels (p<0.00017), and CRP levels and B symptoms (p<0.001). Furthermore there is a significant relationship between CRP and LDH levels (p<0.042).These results indicated that CRP may be considered as a valuable and easy prognostic biomarker of NHL.Keywords
This publication has 23 references indexed in Scilit:
- Cytokines in malignant lymphomas: Review and prospective evaluationHuman Pathology, 1993
- Characterization of a new IL-6-dependent human B-lymphoma cell line in long term cultureCytokine, 1993
- Cytokine (Interleukin-1 alpha, Interleukin-1 beta, Tumor Necrosis Factor alpha, and Interleukin-6)-Possessing Cells in Lymph Nodes of Malignant LymphomaPathology - Research and Practice, 1993
- Pathogenic significance of interleukin-6 in angioimmunoblastic lymphadenopathy-type T-cell lymphomaHuman Pathology, 1993
- Interleukin-6 in Biology and MedicineAdvances in Immunology, 1993
- Intratumoral Production of IL-6 in B Cell Chronic Lymphocytic Leukemia and B LymphomasLeukemia & Lymphoma, 1993
- Long-Term Consequences of Interleukin-6 Overexpression in Transgenic MiceDNA and Cell Biology, 1992
- Interleukin-6 production in high-grade B lymphomas: correlation with the presence of malignant immunoblasts in acquired immunodeficiency syndrome and in human immunodeficiency virus-seronegative patientsBlood, 1992
- A possible autocrine role for interleukin-6 in two lymphoma cell linesBlood, 1989
- Interleukin 6 gene expression in normal and neoplastic B cells.Journal of Clinical Investigation, 1989